title: HIV Drug to Aid Melanoma Therapies?
abstract: The HIV1 protease inhibitor nelfinavir is being investigated as a cancer therapeutic. In this issue of Cancer Cell, Smith et al. (2016) report that nelfinavir suppresses MITF expression induced by MAPK pathway inhibition in melanoma cells and sensitizes melanoma cells with NRAS or BRAF plus NRAS mutations to MEK inhibitors.
authors.affiliation: Tumor Initiation and Maintenance Program, Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
authors.forename: Hyungsoo
authors.initials: H
authors.lastname: Kim
authors.affiliation: Tumor Initiation and Maintenance Program, Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA. Electronic address: zeev@ronailab.net.
authors.forename: Ze'ev A
authors.initials: ZA
authors.lastname: Ronai
mesh_terms: D004361:Drug Tolerance / Q000235:genetics*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics*; D009154:Mutation / Q000187:drug effects* / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*
chemical_list: D047428:Protein Kinase Inhibitors